Physician profile
David E Hardesty
NPI 1942239157
$26,822.51
in general payments reported to CMS, 2019-2025
25 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,551 · 2020: $1,073 · 2021: $8,184 · 2022: $7,424 · 2023: $21.21 · 2024: $326 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20,176.21 | 2019-2022 | |
| Acorda Therapeutics, INC | $4,503.66 | 2019-2020 | |
| Abbvie INC. | $402.30 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $224.08 | 2019 | |
| Medtronic, INC. | $179.38 | 2021-2025 | Percept PC Brainsense |
| Abbott Laboratories | $166.25 | 2021-2025 | Infinity |
| Boston Scientific Corporation | $165.84 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $157.61 | 2019 | |
| Mdd US Operations, LLC | $143.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.02 | 2019 | |
| Lilly USA, LLC | $75.85 | 2019 | |
| Biogen, INC. | $69.21 | 2019 | |
| Neurocrine Biosciences, INC. | $62.07 | 2019 | |
| Amneal Pharmaceuticals LLC | $59.98 | 2019 | |
| Genentech USA, INC. | $53.24 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.80 | 2019 | |
| Kyowa Kirin, INC. | $36.61 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $30.97 | 2024 | |
| Amgen INC. | $26.76 | 2019 | |
| Greenwich Biosciences, INC. | $19.73 | 2019 | |
| Emd Serono, INC. | $19.34 | 2019 | |
| Ucb, INC. | $18.72 | 2019 | |
| Allergan, INC. | $18.07 | 2019 | |
| Adamas Pharmaceuticals, INC. | $17.68 | 2019 | |
| Grifols USA, LLC | $17.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.